Cannibas, page-2

First 2 Last

Share
Profile

Follow
Macleod22

4,855 Posts.

171

28/05/15

02:38

Post #: 15364624
Share

Originally posted by MACLEOD22 ↑

IGS has announced a change in strategy and direction moving into medical cannibas via association with Winter Gardens Biosciences.

Any yet all I have read about on this forum of late is not of its potential but of its directors and past flops. No credence given to Julian Strauss and his team and potential global markets.

Move on guys and do some research about where this new venture may take shareholders. There is so much info in the market place with new entrants wanting a piece of the action.

Directors would not have embraced this opportunity without knowledge of backers. In turn WG would have been offered some guarantee that financing is available.

In time we may gain an appreciation that this venture will be a company maker and dissolve the past failures. Thats what I am hoping for.

I agree that the financials look shithouse. However I have read that Santa Fe Gold (Quarterly just released) which is in bigger difficulty and could go under together with IGSs debt outstanding may resurrect via a copper project JV. If this comes off then maybe IGS coffers will be replenished? This is just another aspect to investigate in your research while embracing KIWIs alarms.

Will be interesting in a few weeks time when shareholders need to make a call on WG.

CHEERS

Expand

Just for starters go across and read about Phytotech ASX PYL short history. This is a stock which sees value in the cannibas sector. Well supported.

No reason why Winter Gardens cannot offer shareholders a similar value equation in time.

There are others like Capital Mining wanting action.

This new medical horizon has potential. Thats why I have invested in cannibas.

IGS Price at posting: 0.4¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

TI1

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HAW

Hastings progressing Yangibana to production with lower costs

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZNO

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

The iron ore comeback: Can it last?